Navigation Links
FDA Advisory Committee Recommends Approval for Boehringer Ingelheim's Olodaterol for Maintenance Treatment of COPD
Date:1/29/2013

RIDGEFIELD, Conn., Jan. 29, 2013 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended that clinical data included in a new drug application (NDA) provide substantial and convincing evidence to support the approval of olodaterol as a once-daily maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. If approved by the FDA, it is anticipated that olodaterol will be marketed under the brand name Striverdi Respimat in the United States.

"We at Boehringer Ingelheim are pleased with the Advisory Committee's recommendation and look forward to continuing to work with the FDA as the Agency continues its review of the olodaterol NDA," said Tunde Otulana , MD, vice president, Clinical Development and Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc.  "The positive vote from the Advisory Committee marks an important step towards making olodaterol available to the approximately 24 million patients with COPD in the United States."

The Committee also voted affirmatively that data showed the efficacy and safety of olodaterol supports approval of the 5 microgram dose. 

The Committee reviewed data from the Phase 3 olodaterol clinical trial program, including data from the 48-week and 6-week duration trials. These data are part of the NDA being reviewed to establish that olodaterol delivered once daily at the 5 microgram dose showed improvements in lung function, as measured by forced expiratory volume in one second (FEV1), in patients with moderate to very severe COPD compared to placebo and also active comparators.

The trials were conducted in a patient population represent
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
3. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
4. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
5. Generex Augments Antigen Express Scientific Advisory Board
6. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
7. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
8. Marken Announces Global Advisory Board
9. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
10. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
11. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Oct. 27 According to Millennium Research Group ... intelligence, the European arthroscope market generated over $30 ... over 2009 due to decreasing scope prices and ... Due to unfavorable economic conditions, manufacturers are ...
... today announced that it has received approval from the ... (US 7,815,929) regarding a method for the preparation, storage ... very nature, the process of compounding suppositories is cumbersome, ... Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. ...
Cached Medicine Technology:Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 2Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 3CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding 2
(Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Risperdal lawsuit ... a mass tort litigation currently underway in Pennsylvania’s Philadelphia ... As of December 24, 2014, court documents indicate that ... behalf of individuals who developed gynecomastia (male breast growth) ... from the Court indicates that this represents an increase ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, ... and launched a site-wide wedding gown promotion. , ... in a more unexpected way, the collection should be a ... the global market, and they are available with custom service. ... at discounted prices, up to 75% off; most of them ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... which is used in the treatment of colon or ... also prescribed to patients who suffer from advanced gastrointestinal ... a multi-kinase inhibitor and it blocks many enzymes which ...
Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... WASHINGTON, D.C.Exemplary work in genetic imaging and therapy have ... & Molecular Biology at Jefferson Medical College of Thomas ... at Jefferson, recognition by his peers as a 2010 ... Science (AAAS). AAAS is honoring Dr. Wickstrom for ...
... HealthDay Reporter , TUESDAY, Jan. 11 (HealthDay News) ... attitude: The most optimistic adolescents may be somewhat less likely ... have found a slight link between optimism and less heavy ... new research, on kids in Australia, doesn,t prove that optimism ...
... a common problem for patients with schizophrenia. The increased tendency ... smoke, but to do so more heavily than the general ... acting as a treatment for some symptoms of schizophrenia. ... those with high and low affinity for nicotine. The low ...
... remains an unresolved issue as to whether interstitial brachytherapy has ... prostate cancer, nor do newer studies provide proof in this ... the Institute for Quality and Efficiency in Health Care (IQWiG) ... newer studies challenged the findings of research already completed in ...
... risk of an ectopic pregnancy because of a lasting effect ... the first time of how chlamydia can increase the risk ... implants outside the womb, in the Fallopian tube. Researchers ... had the sexually transmitted infection were more likely to produce ...
... HealthDay Reporter , TUESDAY, Jan. 11 (HealthDay News) -- The ... on Saturday will likely cause some permanent damage, but experts ... be. However, doctors at University Medical Center in Tucson ... are already encouraged by her ability to follow simple instructions. ...
Cached Medicine News:Health News:Optimism Could Help Kids Keep Depression at Bay 2Health News:Targeting nicotine receptors to treat cognitive impairments in schizophrenia 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 3Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 4Health News:Wounded Congresswoman Responds to Simple Commands 2Health News:Wounded Congresswoman Responds to Simple Commands 3Health News:Wounded Congresswoman Responds to Simple Commands 4
... SYSCAN3® Hospital Test Kit is a multi-well ELISA ... in a standard serology laboratory without the need ... specific antigen preparation from Candida albicans. Our SYSCAN3 ... the presence of antibodies to Candida in the ...
Immunodiffusion tests are used for the detecion of precipitating antibodies (primarily of the IgG and IgA classes) against antigens of C. albicans. The presence of precipitating antibodies indicates ...
... Health Record streamlines patient information management ... A flexible and easily customizable solution, ... financial benefits. HealthMatics EHR organizes communication ... and with outside practitioners. It also ...
... generation of advanced Electronic Medical Records (EMR) ... numerically codified medical vocabularies in the world. ... embedded in MedcomSoft Record, healthcare providers can ... and intuitive point and click system and ...
Medicine Products: